Mega Genomics Completes Internal Control Overhaul to Meet HKEX Resumption Demands
I'm PortAI, I can summarize articles.
Mega Genomics Limited has completed an internal control overhaul to meet the Hong Kong Stock Exchange's resumption demands. The company engaged Grant Thornton Advisory Services to review its financial processes and internal controls, implementing all recommended corrective measures. This move aims to address regulatory concerns and potentially resume trading, reassuring investors about its governance framework. Mega Genomics is listed on the HKEX and operates under compliance with Hong Kong's regulations, with a current market cap of HK$1.61B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments